Lynx1 Capital Management LP 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 09:07 am Sale |
2024-09-30 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 37,436 2.800% |
-84,762 (-69.36%) |
Filing |
| 2024-02-14 09:19 am Purchase |
2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 122,198 9.900% |
51,841 (+73.68%) |
Filing |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 70,357 7.600% |
22,550 (+47.17%) |
Filing |
| 2022-10-24 4:57 pm Purchase |
2022-10-13 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Lynx1 Capital Management LP | 47,808 5.100% |
47,808 (New Position) |
Filing |